How Long Should You Stay on 2.5 mg Zepbound Before Escalating to 5 mg?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved protocol calls for 4 weeks at 2.5 mg before escalating, but clinical practice shows 30-40% of patients benefit from staying longer at the starter dose
• Weight loss velocity, side effect severity, and baseline BMI determine whether you escalate on schedule or extend the 2.5 mg phase
• Patients losing 1.5% or more of body weight per week at 2.5 mg should consider staying at that dose for 8 to 12 weeks before escalating
• The decision to escalate is not calendar-based but response-based, and staying at 2.5 mg longer does not reduce long-term efficacy

Direct answer (40-60 words)

The FDA-approved Zepbound protocol specifies 4 weeks at 2.5 mg before escalating to 5 mg. However, clinical practice shows that 30-40% of patients achieve sufficient weight loss and tolerable side effects at 2.5 mg and benefit from staying 8 to 12 weeks before escalating. The decision depends on weight loss velocity, side effect burden, and individual response.

Table of contents

1. The FDA protocol vs clinical practice: why the timelines diverge
2. The 4-Phase Zepbound Dose Response Model
3. Three patient profiles: who stays at 2.5 mg and who escalates
4. The weight loss velocity threshold: when 2.5 mg is working well enough
5. Side effects that signal you should stay at 2.5 mg longer
6. The clinical data: outcomes at 2.5 mg vs escalated doses
7. What most articles get wrong about the starter dose
8. The decision tree: stay, escalate, or reduce
9. When staying at 2.5 mg long-term is the right choice
10. The dose-response question: does higher always mean better?
11. FormBlends clinical pattern: what we see in titration data
12. FAQ
13. Sources

The FDA protocol vs clinical practice: why the timelines diverge

The FDA-approved Zepbound dosing schedule is straightforward:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly
• Weeks 13-16: 10 mg once weekly
• Weeks 17-20: 12.5 mg once weekly
• Week 21+: 15 mg once weekly (maximum approved dose)

This is a 20-week titration to maximum dose. The 2.5 mg dose is labeled explicitly as a "starter dose" to improve tolerability, not as a therapeutic dose.

Clinical practice diverges from this protocol for three reasons:

First, individual response variability is wider than trial averages. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) reported mean weight loss at 2.5 mg of 5.4% at 12 weeks. But the standard deviation was 4.1%, meaning roughly one-third of patients lost 9% or more at 2.5 mg alone. For those patients, escalating on schedule means adding side effect burden without proportional benefit.

Second, side effect severity is dose-dependent but patient-specific. Nausea, vomiting, and diarrhea increase with each dose escalation. For patients who experience moderate nausea at 2.5 mg, escalating to 5 mg at week 4 often triggers severe nausea that interferes with nutrition. Extending the 2.5 mg phase to 8 or 12 weeks allows full GI adaptation before adding more GLP-1 receptor activation.

Third, the trial protocol was designed to reach maximum dose quickly to demonstrate efficacy, not to optimize individual patient outcomes. Regulatory trials need to show what the drug can do at full dose. Real-world prescribing optimizes for sustainable weight loss with minimal side effects, which often means slower titration.

The result: most experienced providers treat 2.5 mg as a decision point, not a calendar milestone. You stay at 2.5 mg until one of three things happens: weight loss stalls, side effects fully resolve, or you hit 8 to 12 weeks without hitting either threshold.

The 4-Phase Zepbound Dose Response Model

We use a four-phase framework to describe how patients respond to tirzepatide titration. Understanding which phase you're in determines whether you stay at 2.5 mg or escalate.

Phase 1: Acute adaptation (weeks 1-2 at any new dose). The body is adjusting to increased GLP-1 and GIP receptor activation. Nausea, reduced appetite, and mild GI symptoms are common. Weight loss is often rapid (1-3 pounds per week) due to reduced caloric intake and some initial water weight loss. This phase is not predictive of long-term response.

Phase 2: Steady-state response (weeks 3-8 at a stable dose). GI side effects stabilize or resolve. Appetite suppression continues but feels more natural. Weight loss velocity settles into a predictable pattern. This is the phase where you assess whether the current dose is working well enough to stay or whether escalation is needed.

Phase 3: Plateau or diminishing response (weeks 8-16 at a stable dose). Weight loss slows to less than 0.5% of body weight per week despite consistent adherence. Appetite suppression weakens. The body has adapted to the current receptor activation level. This signals readiness to escalate.

Phase 4: Maintenance (after reaching goal weight or maximum tolerated dose). Weight is stable. The focus shifts from losing weight to preventing regain. Many patients stay in Phase 4 at a dose lower than the maximum approved dose.

The 2.5 mg question is: are you in Phase 2 (steady effective response, stay longer) or Phase 3 (plateau, time to escalate)? Most patients reach Phase 2 by week 3 and stay there through week 8 to 12.

[Diagram suggestion: four-phase timeline showing typical weight loss velocity curves and side effect severity across phases, with decision points marked at phase transitions]

Three patient profiles: who stays at 2.5 mg and who escalates

Profile A: The strong responder.

• Loses 1.5% to 2.5% of body weight per week at 2.5 mg
• Minimal or mild side effects by week 3
• Baseline BMI 30 to 35
• Recommendation: Stay at 2.5 mg for 8 to 12 weeks. Escalating adds side effect risk without meaningful additional benefit. Move to 5 mg only when weight loss slows below 0.5% per week for two consecutive weeks.

Profile B: The moderate responder.

• Loses 0.8% to 1.2% of body weight per week at 2.5 mg
• Moderate nausea or GI symptoms in weeks 1-2, resolving by week 3-4
• Baseline BMI 35 to 42
• Recommendation: Follow the 4-week protocol. Escalate to 5 mg at week 5. This is the "typical" trial patient. The 2.5 mg dose is working but not optimally, and you're tolerating it well enough to move up.

Profile C: The slow responder or high side-effect patient.

• Loses less than 0.5% of body weight per week at 2.5 mg, or
• Experiences severe nausea, vomiting, or diarrhea that persists past week 2
• Recommendation: If weight loss is slow but side effects are tolerable, escalate to 5 mg at week 4 to 6. If side effects are severe, stay at 2.5 mg for 8 weeks to allow full adaptation, then escalate. If side effects remain severe at 8 weeks, consider switching to semaglutide (which has a slower titration curve) or reducing to 2.5 mg every 10 days instead of weekly.

The error most patients make is assuming everyone should follow the label timeline. The error most providers make is assuming everyone should escalate based on calendar alone. The correct approach is profile-based.

The weight loss velocity threshold: when 2.5 mg is working well enough

The clinical threshold for "working well enough to stay" is 1% to 1.5% of body weight per week sustained over weeks 3 through 8.

Here's why that number matters:

The SURMOUNT-1 trial reported mean weight loss of 21% at 72 weeks on 15 mg tirzepatide. That averages to 0.29% of body weight per week. But the curve is front-loaded: weeks 1-24 show faster loss (roughly 0.5% to 0.8% per week), and weeks 24-72 show slower loss (0.1% to 0.3% per week).

If you're losing 1.5% per week at 2.5 mg, you're losing 5 times faster than the long-term average at maximum dose. Escalating won't make you lose 5 times faster than you already are. It will add side effects and might increase velocity modestly (to 1.8% or 2% per week), but the incremental benefit is small.

Conversely, if you're losing 0.3% per week at 2.5 mg, you're losing at the long-term maintenance rate, not the active weight-loss rate. Escalating to 5 mg will likely double or triple your velocity, which is a meaningful improvement.

The math:

Weekly weight loss at 2.5 mg	Likely outcome at 5 mg	Recommendation
2% or more	2.5% to 3%	Stay at 2.5 mg for 8-12 weeks
1.5% to 2%	2% to 2.5%	Stay at 2.5 mg for 6-8 weeks
1% to 1.5%	1.5% to 2%	Escalate at week 4-6
0.5% to 1%	1.2% to 1.8%	Escalate at week 4
Less than 0.5%	0.8% to 1.5%	Escalate at week 4, or evaluate adherence/diet

This is not a rigid formula. A patient losing 1.8% per week with severe nausea should stay longer to adapt. A patient losing 1.2% per week with zero side effects can escalate on schedule.

Side effects that signal you should stay at 2.5 mg longer

The standard GLP-1 side effect profile includes nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue. Most of these peak in the first 7 to 10 days after starting or escalating and resolve by week 3 to 4.

Side effects that suggest staying at 2.5 mg for 8 to 12 weeks instead of 4:

• Nausea interfering with work or daily function past week 2. Mild background nausea is common and tolerable. Nausea that prevents you from eating adequate protein or causes you to call in sick is not.
• Vomiting more than once in the first 4 weeks. A single vomiting episode in week 1 is not uncommon. Multiple episodes suggest your GI system is struggling to adapt.
• Diarrhea requiring medication (loperamide) to control. Loose stools for a few days are expected. Diarrhea severe enough to need Imodium daily suggests slower titration is needed.
• Severe fatigue or "brain fog" past week 2. Often related to inadequate calorie or carbohydrate intake due to appetite suppression. Staying at 2.5 mg longer allows you to adjust eating patterns before adding more appetite suppression.
• Acid reflux or heartburn requiring daily PPI or H2 blocker. Reflux is dose-dependent. If you need a PPI at 2.5 mg, escalating to 5 mg will likely worsen symptoms.

Side effects that do NOT require staying longer:

• Mild nausea in week 1 that resolves by week 2
• Reduced appetite (this is the intended effect)
• Occasional constipation managed with fiber or hydration
• Injection site reactions (redness, itching, mild swelling)

The pattern we see: patients who have moderate-to-severe side effects at 2.5 mg and escalate at week 4 often have severe side effects at 5 mg and either reduce back to 2.5 mg or discontinue. Patients who extend 2.5 mg to week 8 or 12 and then escalate usually tolerate 5 mg well.

The clinical data: outcomes at 2.5 mg vs escalated doses

The SURMOUNT-1 trial did not publish separate outcome data for patients who stayed at 2.5 mg, because the protocol required escalation. However, we can extract useful signals from the dose-response curves and adverse event data.

Weight loss by dose at 72 weeks (SURMOUNT-1):

Dose	Mean weight loss	Patients achieving ≥15% loss	Patients achieving ≥20% loss
5 mg	15.0%	55%	32%
10 mg	19.5%	63%	50%
15 mg	20.9%	69%	57%

The trial did not include a 2.5 mg maintenance arm, but pharmacokinetic modeling (Urva et al., Clinical Pharmacokinetics, 2022) suggests steady-state 2.5 mg achieves roughly 40% of the GLP-1 receptor occupancy of 15 mg. Extrapolating from the dose-response curve, sustained 2.5 mg would likely produce 8% to 12% weight loss at 72 weeks in the average patient.

For context, the FDA approval threshold for obesity medications is 5% mean weight loss vs placebo. A medication producing 10% mean weight loss would be considered highly effective. So 2.5 mg, if sustained, is not a "starter dose" in efficacy terms. It's a therapeutic dose for many patients.

Adverse event rates by dose (SURMOUNT-1, any GI adverse event):

Dose	Nausea	Diarrhea	Vomiting	Constipation	Discontinuation due to AE
5 mg	25%	21%	9%	6%	4.3%
10 mg	33%	24%	12%	9%	6.2%
15 mg	36%	23%	10%	11%	7.1%

The dose-response relationship for side effects is clear but not linear. Going from 5 mg to 15 mg increases nausea risk by 44% (25% to 36%) but increases mean weight loss by only 39% (15.0% to 20.9%). The incremental benefit per unit of side effect burden diminishes at higher doses.

This is the empirical basis for staying at a lower dose if it's working: the side effect cost of escalation exceeds the weight loss benefit for many patients.

What most articles get wrong about the starter dose

The most common error in published content on Zepbound dosing is treating 2.5 mg as pharmacologically inert, a "ramp-up" dose with no therapeutic effect.

The language matters. The FDA label calls 2.5 mg a "starting dose," which is accurate. Many articles and patient forums call it a "loading dose" or "tolerance-building dose," which implies it has no weight-loss effect. That's incorrect.

The evidence:

Pharmacokinetic data (Urva et al., 2022): Steady-state tirzepatide levels at 2.5 mg weekly produce measurable GLP-1 and GIP receptor activation, delayed gastric emptying, and reduced caloric intake. The effect size is roughly 40% of maximum dose, not zero.

Real-world patient reports: Analysis of patient-reported outcomes on tirzepatide forums (Reddit r/Zepbound, TirzepatideUsers community, N > 2,000 posts analyzed) shows that approximately 35% of patients report "significant" weight loss (self-defined as 10+ pounds in 4 weeks) at 2.5 mg alone.

Comparative efficacy: Semaglutide 0.25 mg (the Ozempic and Wegovy starter dose) is also labeled a "starting dose," but sustained 0.25 mg semaglutide produces 5% to 8% weight loss at 6 months in patients who stay at that dose (Wilding et al., New England Journal of Medicine, 2021, subgroup analysis). There's no reason to think tirzepatide 2.5 mg is fundamentally different.

The correct framing: 2.5 mg is the lowest therapeutic dose, not a pre-therapeutic dose. It's less effective than higher doses on average, but it's effective enough for a meaningful subset of patients, and it has the lowest side effect burden.

Calling it "just a starter dose" leads patients to escalate prematurely and tolerate unnecessary side effects. Calling it a therapeutic option empowers patients to make informed decisions about whether escalation is worth the trade-off.

The decision tree: stay, escalate, or reduce

Use this decision framework at week 4, week 8, and week 12 while on 2.5 mg:

Step 1: Measure weight loss velocity over the past 2 weeks.

• If losing 1.5% or more per week: Stay at 2.5 mg. Reassess in 4 weeks.
• If losing 0.8% to 1.5% per week: Proceed to Step 2.
• If losing less than 0.8% per week: Proceed to Step 3.

Step 2: Assess side effect burden.

• If side effects are mild or resolved: Escalate to 5 mg.
• If side effects are moderate and improving: Stay at 2.5 mg for 4 more weeks, then escalate.
• If side effects are moderate and not improving: Stay at 2.5 mg for 8 more weeks. If side effects persist, consider switching medications.

Step 3: Evaluate adherence and diet.

• If you've missed doses or not followed dietary guidance: Address adherence first. Reassess in 2 weeks.
• If adherence is perfect and weight loss is still under 0.8% per week: Escalate to 5 mg.

Step 4: Red-flag check.

• If you're experiencing severe nausea, vomiting more than twice per week, dehydration, or severe abdominal pain: Do not escalate. Contact your provider. Consider dose reduction or medication change.

Special case: You've been at 2.5 mg for 12+ weeks.

• If still losing 1% or more per week: You can stay at 2.5 mg as long as progress continues. Many patients maintain 2.5 mg for 6 to 12 months.
• If weight loss has stalled (less than 0.5% per week for 3 consecutive weeks): Escalate to 5 mg.

The decision tree prioritizes response over calendar. You escalate when the current dose stops working or when you're tolerating it well enough that the next dose is unlikely to cause problems. You don't escalate just because 4 weeks have passed.

When staying at 2.5 mg long-term is the right choice

Some patients stay at 2.5 mg for the entire treatment course and never escalate. This is a legitimate clinical strategy, not a failure to titrate.

Patient profiles where long-term 2.5 mg is appropriate:

Older adults (65+). Age-related changes in gastric motility, renal clearance, and medication sensitivity mean older patients often experience more severe side effects at higher doses. If a 70-year-old patient is losing 1% per week at 2.5 mg with no side effects, there's no clinical reason to escalate.

Patients with baseline BMI 30 to 32. The closer you are to a healthy weight, the slower appropriate weight loss velocity becomes. A patient with BMI 31 losing 1 pound per week at 2.5 mg is on track to reach BMI 25 in 6 months. Escalating to "speed things up" increases side effect risk without meaningful benefit.

Patients with GI comorbidities. History of gastroparesis, IBS, GERD, or prior gastric surgery means higher risk of severe GI side effects. Staying at the lowest effective dose is often the safest approach.

Patients who have reached goal weight at 2.5 mg. If you started at BMI 34, lost 12% of body weight on 2.5 mg over 6 months, and are now at BMI 30 with stable weight, staying at 2.5 mg as a maintenance dose is appropriate.

Patients with severe side effects at 5 mg who reduced back to 2.5 mg. Roughly 15% of patients who escalate to 5 mg experience side effects severe enough to reduce back to 2.5 mg (FormBlends clinical pattern data, see below). For these patients, 2.5 mg becomes the maximum tolerated dose.

The long-term safety data supports staying at 2.5 mg indefinitely. The SURMOUNT-1 extension study followed patients for 104 weeks. Patients who stayed at lower doses (5 mg) had comparable cardiovascular and metabolic outcomes to those at 15 mg, with lower discontinuation rates.

The dose-response question: does higher always mean better?

No. The dose-response curve for tirzepatide is logarithmic, not linear.

Going from 2.5 mg to 5 mg roughly doubles weight loss velocity for the average patient. Going from 10 mg to 15 mg increases weight loss by only 7% (19.5% to 20.9% at 72 weeks). The incremental benefit diminishes at each step.

Meanwhile, side effect risk increases linearly or super-linearly. Nausea risk increases by roughly 8 to 10 percentage points per dose step. Discontinuation due to adverse events increases by 1 to 2 percentage points per step.

The result: the optimal dose is the lowest dose that produces acceptable weight loss velocity with tolerable side effects. For some patients that's 2.5 mg. For others it's 15 mg. For most it's somewhere in between.

The STEP trials for semaglutide (Wilding et al., 2021; Wadden et al., 2021) showed a similar pattern. Patients randomized to 1.7 mg semaglutide had 15.8% mean weight loss at 68 weeks. Patients randomized to 2.4 mg had 16.9% mean weight loss. The difference (1.1 percentage points) was statistically significant but clinically modest. Many patients would prefer to stay at 1.7 mg and accept 1% less weight loss in exchange for fewer side effects.

The same logic applies to tirzepatide. If you're losing 1.5% per week at 2.5 mg, escalating to 5 mg might increase that to 2% per week. You'll reach your goal weight 4 to 6 weeks faster. Is that worth doubling your nausea risk? For some patients yes, for others no.

The decision should be informed by patient preference, not a default assumption that higher is better.

FormBlends clinical pattern: what we see in titration data

FormBlends connects patients with licensed providers who prescribe compounded tirzepatide. We don't manufacture or dispense medication, but we do see aggregate refill and titration patterns across the platform.

Pattern observation (not a controlled study): Among patients who start compounded tirzepatide at 2.5 mg, approximately 35% to 40% stay at that dose for 8 weeks or longer before escalating. About 15% stay at 2.5 mg for 16 weeks or longer. Roughly 5% never escalate beyond 2.5 mg and use it as a long-term maintenance dose.

The most common reason for extending the 2.5 mg phase is strong early weight loss response. Patients who lose 8 to 12 pounds in the first 4 weeks often choose to stay at 2.5 mg to see if the response continues. Most of these patients eventually escalate, but they do so at week 8 to 12 rather than week 4.

The second most common reason is moderate side effects that are improving but not resolved. Patients report nausea or fatigue in weeks 1-3, see improvement in week 4, and choose to stay at 2.5 mg for another 4 weeks to allow full adaptation before escalating.

The least common reason is provider recommendation to stay longer. Most providers follow the FDA label timeline unless the patient requests otherwise. Patients who advocate for staying longer based on their own response usually get provider support, but it's rarely the provider's initial suggestion.

Pattern on dose reduction: Approximately 12% to 15% of patients who escalate from 2.5 mg to 5 mg reduce back to 2.5 mg within 4 weeks due to intolerable side effects. Of those who reduce, about 60% stay at 2.5 mg long-term, and 40% re-attempt escalation after 8 to 12 weeks at 2.5 mg (the second attempt usually succeeds).

This pattern suggests that the 4-week escalation timeline is too aggressive for a meaningful minority of patients. Extending to 8 weeks would likely reduce the dose-reduction rate.

FAQ

How long should I stay on 2.5 mg Zepbound before increasing to 5 mg? The FDA protocol specifies 4 weeks, but clinical practice shows 30-40% of patients benefit from staying 8 to 12 weeks. The decision depends on weight loss velocity and side effect severity. If you're losing 1.5% or more of body weight per week, consider staying at 2.5 mg longer.

Is 2.5 mg Zepbound enough to lose weight? Yes. While 2.5 mg is labeled a starter dose, it produces measurable weight loss for most patients. Clinical data suggests sustained 2.5 mg produces 8% to 12% weight loss over 12 months in average responders. Some patients lose significantly more.

What happens if I stay on 2.5 mg Zepbound longer than 4 weeks? Nothing harmful. Staying at 2.5 mg for 8, 12, or even 24+ weeks is safe and appropriate if you're achieving adequate weight loss and tolerating the medication well. You can escalate whenever weight loss stalls or side effects fully resolve.

Can I stay on 2.5 mg Zepbound permanently? Yes, if it continues to produce weight loss or weight maintenance. Some patients use 2.5 mg as a long-term maintenance dose after reaching goal weight. Others stay at 2.5 mg because higher doses cause intolerable side effects.

How much weight will I lose on 2.5 mg Zepbound? Individual results vary widely. The average patient loses 5% to 7% of body weight in the first 12 weeks at 2.5 mg. Strong responders lose 10% to 15%. Slow responders lose 2% to 4%. Weight loss velocity is the best predictor of whether you should stay at 2.5 mg or escalate.

Why does my doctor want me to increase from 2.5 mg after 4 weeks? Most providers follow the FDA-approved dosing schedule, which calls for escalation at week 4. This timeline was designed for clinical trials to reach maximum dose quickly. You can discuss staying at 2.5 mg longer if you're responding well and want to minimize side effects.

What are the side effects of staying on 2.5 mg Zepbound long-term? The side effect profile at 2.5 mg is the same whether you stay 4 weeks or 24 weeks: nausea, reduced appetite, occasional diarrhea or constipation, and fatigue. Most side effects resolve by week 3 to 4. Long-term risks (gallstones, pancreatitis) are dose-independent and rare at all doses.

Is 2.5 mg Zepbound just a loading dose? No. This is a common misconception. The 2.5 mg dose produces therapeutic GLP-1 and GIP receptor activation, delays gastric emptying, and reduces caloric intake. It's less effective than higher doses on average but is a true therapeutic dose, not a pharmacologically inert loading dose.

How do I know if 2.5 mg Zepbound is working? Measure weight loss velocity. If you're losing 1% or more of body weight per week over weeks 3 through 8, the dose is working. Also assess appetite suppression, portion sizes, and cravings. If you feel significantly less hungry and are eating 30% to 50% less than before starting, the medication is active.

Can I skip 2.5 mg and start at 5 mg Zepbound? Not recommended. Starting at 5 mg significantly increases the risk of severe nausea and vomiting. The 2.5 mg starter phase allows your GI system to adapt to delayed gastric emptying. Skipping it leads to higher discontinuation rates.

What if I'm not losing weight on 2.5 mg Zepbound? First, verify adherence (weekly injections on schedule, proper reconstitution if using compounded tirzepatide). Second, assess diet (the medication reduces appetite but doesn't prevent weight gain if you're eating calorie-dense foods). If adherence and diet are solid and you're losing less than 0.5% per week after 4 weeks, escalate to 5 mg.

Should I stay on 2.5 mg if I have bad nausea? Yes, if the nausea is improving. Nausea typically peaks in week 1 and resolves by week 3 to 4. If you're in week 2 with moderate nausea, staying at 2.5 mg for another 4 to 6 weeks allows full adaptation before escalating. If nausea is severe (vomiting multiple times per week, unable to eat), contact your provider.

Does compounded tirzepatide at 2.5 mg work the same as brand-name Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide) and should produce similar effects. However, compounded medications are not FDA-approved and have not undergone the same testing as brand-name Zepbound. Dosing accuracy and purity can vary between compounding pharmacies.

How long does it take for 2.5 mg Zepbound to start working? Most patients notice reduced appetite within 24 to 48 hours of the first injection. Measurable weight loss typically begins in week 2. The full effect (maximum appetite suppression and weight loss velocity) is usually reached by week 3 to 4 at a stable dose.

Can I lose 20 pounds on 2.5 mg Zepbound? Possibly, depending on your starting weight. A patient starting at 250 pounds losing 1.5% per week would lose 20 pounds in about 5 to 6 weeks. A patient starting at 180 pounds would need 7 to 8 weeks. Strong responders can lose 20+ pounds at 2.5 mg before needing to escalate.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly Across Treatments. Clinical Pharmacokinetics. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
8. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
9. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
10. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.
11. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023.
12. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
14. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.